The BMS IDO1 inhibitor, BMS-986242, is a clinical candidate in a Ph. I/II study in combination with nivolumab for cancer. Like me, you probably had to look twice at…
Home > BMS-986242
this content is exclusive to
Premium members
Unlock this content with a Premium membership to read it now.